HC Wainwright Comments on BioAtla, Inc.’s FY2028 Earnings (NASDAQ:BCAB)

BioAtla, Inc. (NASDAQ:BCAB) – Analysts at HC Wainwright issued their FY2028 earnings estimates for shares of BioAtla in a report issued on Wednesday, March 27th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.09) for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($2.33) per share.

Separately, JMP Securities reiterated a “market outperform” rating and set a $12.00 target price on shares of BioAtla in a research report on Thursday.

BioAtla Price Performance

NASDAQ BCAB opened at $3.44 on Friday. The company’s fifty day moving average is $2.50 and its two-hundred day moving average is $2.09. BioAtla has a 52-week low of $1.24 and a 52-week high of $4.07. The firm has a market capitalization of $164.91 million, a price-to-earnings ratio of -1.33 and a beta of 1.02.

Hedge Funds Weigh In On BioAtla

A number of institutional investors have recently modified their holdings of the stock. Swiss National Bank raised its stake in shares of BioAtla by 17.8% during the first quarter. Swiss National Bank now owns 50,200 shares of the company’s stock worth $251,000 after buying an additional 7,600 shares during the last quarter. BlackRock Inc. raised its stake in shares of BioAtla by 0.5% during the first quarter. BlackRock Inc. now owns 1,594,238 shares of the company’s stock worth $7,970,000 after buying an additional 8,344 shares during the last quarter. Ergoteles LLC bought a new stake in shares of BioAtla during the first quarter worth approximately $79,000. Prudential Financial Inc. acquired a new position in BioAtla during the first quarter valued at approximately $130,000. Finally, XTX Topco Ltd acquired a new position in BioAtla during the first quarter valued at approximately $91,000. 77.23% of the stock is owned by institutional investors.

About BioAtla

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.